JP2023501584A5 - - Google Patents
Info
- Publication number
- JP2023501584A5 JP2023501584A5 JP2022527735A JP2022527735A JP2023501584A5 JP 2023501584 A5 JP2023501584 A5 JP 2023501584A5 JP 2022527735 A JP2022527735 A JP 2022527735A JP 2022527735 A JP2022527735 A JP 2022527735A JP 2023501584 A5 JP2023501584 A5 JP 2023501584A5
- Authority
- JP
- Japan
- Prior art keywords
- radiation
- diffraction pattern
- ray powder
- powder diffraction
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025153291A JP2026012675A (ja) | 2019-11-13 | 2025-09-16 | Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935007P | 2019-11-13 | 2019-11-13 | |
| US62/935,007 | 2019-11-13 | ||
| PCT/US2020/060575 WO2021097339A1 (en) | 2019-11-13 | 2020-11-13 | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153291A Division JP2026012675A (ja) | 2019-11-13 | 2025-09-16 | Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501584A JP2023501584A (ja) | 2023-01-18 |
| JP2023501584A5 true JP2023501584A5 (https=) | 2023-11-20 |
Family
ID=73856569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527735A Pending JP2023501584A (ja) | 2019-11-13 | 2020-11-13 | Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 |
| JP2025153291A Pending JP2026012675A (ja) | 2019-11-13 | 2025-09-16 | Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153291A Pending JP2026012675A (ja) | 2019-11-13 | 2025-09-16 | Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12006318B2 (https=) |
| EP (1) | EP4058456A1 (https=) |
| JP (2) | JP2023501584A (https=) |
| KR (1) | KR20220101099A (https=) |
| CN (1) | CN114728972B (https=) |
| BR (1) | BR112022009331A2 (https=) |
| CA (1) | CA3158521A1 (https=) |
| IL (1) | IL292755A (https=) |
| MX (1) | MX2022005795A (https=) |
| WO (1) | WO2021097339A1 (https=) |
| ZA (1) | ZA202204943B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4058456A1 (en) | 2019-11-13 | 2022-09-21 | RAPT Therapeutics, Inc. | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof |
| CN121002023A (zh) * | 2023-04-24 | 2025-11-21 | 浙江华海药业股份有限公司 | 趋化因子受体调节剂制备方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| JP2008530211A (ja) * | 2005-02-16 | 2008-08-07 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体のモジュレーターとなる置換ピラゾール |
| TW201024298A (en) * | 2008-09-23 | 2010-07-01 | Palau Pharma Sa | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| JP2013031931A (ja) * | 2011-08-01 | 2013-02-14 | Hitachi Koki Co Ltd | 携帯式作業機 |
| TW201311693A (zh) * | 2011-09-02 | 2013-03-16 | Kyowa Hakko Kirin Co Ltd | 化學激活激素受體活性調節劑 |
| AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| AU2017302635B2 (en) * | 2016-07-29 | 2021-09-16 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| US10246462B2 (en) * | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| JP2020533332A (ja) * | 2017-09-12 | 2020-11-19 | アルデア バイオサイエンシーズ インク． | 障害を処置するためのｃｘｃｒ−２阻害剤 |
| EP3706750A1 (en) | 2017-11-06 | 2020-09-16 | RAPT Therapeutics, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| CN109796457B (zh) * | 2019-03-28 | 2020-03-06 | 苏州国匡医药科技有限公司 | 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用 |
| EP4058456A1 (en) | 2019-11-13 | 2022-09-21 | RAPT Therapeutics, Inc. | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof |
-
2020
- 2020-11-13 EP EP20828597.3A patent/EP4058456A1/en active Pending
- 2020-11-13 JP JP2022527735A patent/JP2023501584A/ja active Pending
- 2020-11-13 US US17/098,157 patent/US12006318B2/en active Active
- 2020-11-13 WO PCT/US2020/060575 patent/WO2021097339A1/en not_active Ceased
- 2020-11-13 BR BR112022009331A patent/BR112022009331A2/pt unknown
- 2020-11-13 KR KR1020227016282A patent/KR20220101099A/ko active Pending
- 2020-11-13 CN CN202080076933.2A patent/CN114728972B/zh active Active
- 2020-11-13 CA CA3158521A patent/CA3158521A1/en active Pending
- 2020-11-13 MX MX2022005795A patent/MX2022005795A/es unknown
-
2022
- 2022-05-03 IL IL292755A patent/IL292755A/en unknown
- 2022-05-05 ZA ZA2022/04943A patent/ZA202204943B/en unknown
-
2024
- 2024-06-07 US US18/737,044 patent/US20240317768A1/en active Pending
-
2025
- 2025-09-16 JP JP2025153291A patent/JP2026012675A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025176008A5 (https=) | ||
| JP2023501584A5 (https=) | ||
| TW201022216A (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
| RU2019104890A (ru) | Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1 | |
| TW201420572A (zh) | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 | |
| EP3436459A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| CA3126330A1 (en) | Dihydroorotate dehydrogenase inhibitors | |
| CA2931022A1 (en) | Imidazopyridine derivatives as modulators of tnf activity | |
| CA3186769A1 (en) | Bicyclic compounds and use thereof | |
| JP2016513704A5 (https=) | ||
| JP4016059B2 (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| US7056934B2 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2024508890A5 (https=) | ||
| US20050020626A1 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2021522348A5 (https=) | ||
| US7091340B2 (en) | Polymorphs | |
| JP2006528623A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| RU2021113671A (ru) | Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1 | |
| WO2024222767A1 (zh) | 双环化合物的晶体形式及其制备方法 | |
| JP2006199700A (ja) | 結晶形態 | |
| RU2023127927A (ru) | Ингибиторы поли(адф-рибоза)полимеразы |